Spironolactone is not a true DHT blocker in the way most people mean when they use that term. It does not stop your body from producing DHT. Instead, it works primarily by blocking DHT (and testosterone) from attaching to androgen receptors in your tissues, preventing those hormones from having their usual effects on skin, hair follicles, and oil glands. The distinction matters because drugs like finasteride actually reduce DHT production, while spironolactone leaves DHT circulating but renders it less effective at the cellular level.
How Spironolactone Actually Works
Spironolactone was originally developed as a blood pressure medication that helps the body shed excess sodium and water. But researchers noticed it had a notable side effect: it interfered with androgens, the hormones responsible for traits like body hair growth, oil production, and certain types of hair loss. That side effect turned out to be therapeutically useful.
At the molecular level, spironolactone competes with DHT for binding sites on androgen receptors. Think of it like a key that fits into the same lock but doesn’t turn it. When spironolactone occupies the receptor, DHT can’t get in and can’t trigger its downstream effects. Lab studies on rat prostate tissue confirmed that spironolactone inhibits DHT from binding to both the cell’s outer and inner receptors, but does not reduce the activity of 5-alpha reductase, the enzyme that converts testosterone into DHT in the first place.
Spironolactone also influences androgen levels through a few secondary pathways. It increases levels of a protein called sex hormone binding globulin, which acts as a sponge that soaks up free testosterone in the bloodstream, leaving less available to convert into DHT. It can also interfere with enzymes involved in testosterone production and increase the rate at which the liver clears testosterone. These combined effects make spironolactone a broad anti-androgen rather than a targeted DHT blocker.
Effects on Skin and Oil Glands
Spironolactone’s ability to oppose DHT at the receptor level has a direct, measurable impact on the skin’s oil glands. At doses of 50 to 100 mg per day, it reduces the rate of sebum (skin oil) production by 30 to 50 percent. This is significant because oversized, overactive oil glands are a core driver of hormonal acne. Lab studies on human facial skin cells showed that spironolactone directly inhibits oil gland cell growth in a dose-dependent fashion, cutting proliferation by 25 percent at very low concentrations and by 50 percent at higher ones. When researchers added testosterone or DHT to the same cells, spironolactone counteracted the growth stimulation from both hormones.
This receptor-blocking action is why spironolactone is commonly prescribed off-label for hormonal acne in women. Typical starting doses are 50 mg daily, gradually increased to 100 to 200 mg daily based on how well it works and how well it’s tolerated.
Effectiveness for Hair Loss
For women with pattern hair loss (androgenetic alopecia), spironolactone’s anti-androgen effects can slow or stop thinning and, in some cases, promote regrowth. Long-term use at standard doses prevents further hair thinning in 85 to 100 percent of women and promotes visible hair growth in 33 to 49 percent. In a randomized, placebo-controlled trial, 38 percent of women on spironolactone achieved moderate-to-marked improvement after 24 weeks, compared to just 9 percent on placebo.
Results take time. Noticeable improvement often requires a full year of consistent use. One study found that clinical improvement rose from 13 percent at 6 months to nearly 70 percent at 12 months when spironolactone was combined with topical minoxidil. This combination of an anti-androgen (to slow the hormonal damage) plus a growth stimulant (to push follicles into active growth) is a common treatment strategy. A separate study using spironolactone at about 139 mg daily alongside low-dose oral minoxidil showed a trend toward greater hair density gains compared to minoxidil alone, though the difference wasn’t statistically significant in that small cohort.
Why It’s Rarely Used in Men
Spironolactone’s broad anti-androgen activity is precisely why it’s almost never prescribed to men for hair loss or acne. Because it blocks androgen receptors throughout the body, not just in the scalp or skin, it can cause feminizing side effects. Breast tissue enlargement or breast pain occurred in 10 percent of men taking just 25 mg per day in a large clinical trial for heart failure. At 150 mg daily, that rate climbed to 52 percent. Decreased libido and erectile dysfunction are also commonly reported.
Men seeking to reduce DHT for hair loss are typically prescribed finasteride or dutasteride instead. These drugs actually inhibit 5-alpha reductase, lowering circulating DHT levels by 60 to 70 percent without broadly blocking androgen receptors. Spironolactone, by contrast, leaves DHT levels largely intact while blocking its action at tissues, which creates a wider hormonal disruption in male bodies.
Important Safety Considerations
For healthy young women, spironolactone is generally well tolerated. Because it’s a potassium-sparing diuretic, there was long-standing concern about dangerously elevated potassium levels. However, updated guidelines from the American Academy of Dermatology (adopted in 2016) and major clinical references now support skipping routine potassium monitoring for healthy young women without kidney disease who are taking spironolactone for skin or hair conditions.
Common side effects include increased urination (especially early on), lighter or irregular periods, breast tenderness, and occasional dizziness. These are generally mild and often improve after the first few months.
The one absolute restriction is pregnancy. Because DHT and testosterone are essential for the normal development of male reproductive organs during embryonic growth, spironolactone’s anti-androgen effects pose a risk of feminizing a male fetus. Animal studies have demonstrated this effect, and at least two human case reports document genital abnormalities in male newborns linked to maternal spironolactone use in early pregnancy. Women of childbearing age who take spironolactone are expected to use reliable contraception throughout treatment.
Spironolactone vs. True DHT Blockers
The simplest way to understand where spironolactone fits is to compare it to medications that genuinely reduce DHT production. Finasteride blocks the enzyme (5-alpha reductase) that converts testosterone to DHT, resulting in significantly lower DHT levels in the blood and tissues. Spironolactone does not meaningfully lower 5-alpha reductase activity even at high concentrations. Instead, it blocks the receptor where DHT would normally act, and it reduces the amount of free testosterone available for conversion.
In practical terms, the end result overlaps: both reduce the biological impact of DHT on hair follicles and oil glands. But calling spironolactone a “DHT blocker” is technically inaccurate. It’s more precisely an androgen receptor antagonist, a drug that blocks the effects of multiple androgens (including DHT and testosterone) rather than targeting DHT production specifically. For women with hormonal acne or pattern hair loss, this broader mechanism is often an advantage, since testosterone itself also drives oil production and follicle miniaturization.